Amyl Therapeutics
Announced 01 Sept 2026$9.6M Β· Series A Β· Hospitals and Health Care Β· Belgium
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating severe peripheral amyloid protein misfolding diseases.
βAmyl Therapeutics has closed an β¬8.25M extension of its Series A round.The funding combines public grants with private investment from family offices, business angels, and existing shareholders Noshaq andMerieux Equity Partners.The LiΓ¨ge-based BioTech is developing a fusion protein platform targeting amyloid-linked diseases, including Alzheimer's aβ
2 more sources tracked. Read the full press release and reporter coverage.
Sign up to read βInvestors: Noshaq, Merieux Equity Partners.